Precision medicine approaches in pancreatic cancer

0 Views

07/13/23

Philip Philip, MD, PhD, FRCP, Wayne State University School of Medicine/Henry Ford Health, Detroit, MI, discusses the feasibility of precision medicine in pancreatic cancer. There are currently known mutations that can be targeted in pancreatic cancer, and next-generation sequencing (NGS) enables the identification of treatable mutations in patients. Additional research is needed to elucidate less common mutations that will results in the development of novel therapies. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.